RNA Drug Delivery Approaches

[1]  M. López‐Fraga,et al.  RNA Interference Technologies and Therapeutics , 2012, BioDrugs.

[2]  C. Eleazu,et al.  Effect of variety on the physico-chemical, carotenoid and microbial loads of flours of five new varieties of sweet potato , 2011 .

[3]  John J Rossi,et al.  RNAi and small interfering RNAs in human disease therapeutic applications. , 2010, Trends in biotechnology.

[4]  A. Santoro,et al.  Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. , 2010, European journal of cancer.

[5]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Daniel G. Anderson,et al.  Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. , 2010, Bioconjugate chemistry.

[7]  Leaf Huang,et al.  Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[8]  D. Rao,et al.  Potential use of RNA interference in cancer therapy , 2010, Expert Reviews in Molecular Medicine.

[9]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  N. Düzgüneş,et al.  Gene delivery by lipoplexes and polyplexes. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  T. Geng,et al.  Flow-through electroporation based on constant voltage for large-volume transfection of cells. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Leaf Huang,et al.  Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Yu-cheng Tseng,et al.  Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[15]  J. Wengel,et al.  Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications , 2010, Chemistry & biodiversity.

[16]  R. Hickerson,et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[18]  Tangui Maurice,et al.  The pharmacology of sigma-1 receptors. , 2009, Pharmacology & therapeutics.

[19]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[20]  T. Park,et al.  siRNA delivery systems for cancer treatment. , 2009, Advanced drug delivery reviews.

[21]  Yu-cheng Tseng,et al.  Lipid-based systemic delivery of siRNA. , 2009, Advanced drug delivery reviews.

[22]  M. Siomi.  Short interfering RNA-mediated gene silencing; towards successful application in human patients. , 2009, Advanced drug delivery reviews.

[23]  J. Rossi,et al.  RNAi-based therapeutics–current status, challenges and prospects , 2009, EMBO molecular medicine.

[24]  M. Tabrizian,et al.  Factors influencing the transfection efficiency of ultra low molecular weight chitosan/hyaluronic acid nanoparticles. , 2009, Biomaterials.

[25]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  B. Wiedenmann,et al.  Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. , 2008, Cancer research.

[27]  Leaf Huang,et al.  An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Shuming Nie,et al.  Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. , 2008, Journal of the American Chemical Society.

[29]  Dexi Liu,et al.  Computer-assisted hydrodynamic gene delivery. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  C. Cho,et al.  Efficient gene delivery using chitosan–polyethylenimine hybrid systems , 2008, Biomedical materials.

[31]  Leaf Huang,et al.  Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[33]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[34]  J. Harborth,et al.  RNAi therapeutics: an update on delivery. , 2008, Current opinion in molecular therapeutics.

[35]  Yuma Yamada,et al.  Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. , 2008, Advanced drug delivery reviews.

[36]  A. Judge,et al.  Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.

[37]  P. Opanasopit,et al.  Evaluation of chitosan salts as non-viral gene vectors in CHO-K1 cells. , 2008, International journal of pharmaceutics.

[38]  David R Corey,et al.  Chemical modification: the key to clinical application of RNA interference? , 2007, The Journal of clinical investigation.

[39]  Michael S. Goldberg,et al.  Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway , 2007, Nature.

[40]  Christiane Garbay,et al.  Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. , 2007, Biochimie.

[41]  R. Stoltenburg,et al.  SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. , 2007, Biomolecular engineering.

[42]  Darren H. Wakefield,et al.  Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.

[43]  M. Maszewska,et al.  Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. , 2007, RNA.

[44]  D. A. Stein,et al.  Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. , 2007, Biochemical Society transactions.

[45]  A. Elmaagacli,et al.  Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia , 2007, Clinical and Experimental Medicine.

[46]  Shiroh Futaki,et al.  Octaarginine-modified multifunctional envelope-type nano device for siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[47]  B. Lebleu,et al.  Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide , 2007, Nucleic acids research.

[48]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[49]  J. Rossi,et al.  RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.

[50]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[51]  Frank Baas,et al.  Evaluation of locked nucleic acid–modified small interfering RNA in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[52]  Mark E. Davis,et al.  Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. , 2007, Bioconjugate chemistry.

[53]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[54]  Ű. Langel,et al.  Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. , 2006, Current opinion in pharmacology.

[55]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[56]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[57]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Shiroh Futaki,et al.  High Density of Octaarginine Stimulates Macropinocytosis Leading to Efficient Intracellular Trafficking for Gene Expression* , 2006, Journal of Biological Chemistry.

[59]  Helmut Ringsdorf,et al.  Polymer therapeutics—polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities* , 2006, Journal of drug targeting.

[60]  R. Schiffelers,et al.  RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[61]  B. Williams,et al.  Activation of the mammalian immune system by siRNAs , 2005, Nature Biotechnology.

[62]  D. Fischer,et al.  Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives , 2005, The journal of gene medicine.

[63]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.

[64]  N. M. Rao,et al.  Haloperidol-associated Stealth Liposomes , 2005, Journal of Biological Chemistry.

[65]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[66]  W. Marshall,et al.  Different delivery methods—different expression profiles , 2005, Nature Methods.

[67]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[68]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[69]  C. Wahlestedt,et al.  Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality , 2005, Nucleic acids research.

[70]  E. Petricoin,et al.  Pathology of the Future: Molecular Profiling for Targeted Therapy , 2005, Cancer investigation.

[71]  Pradeep Tyagi,et al.  Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.

[72]  F André,et al.  DNA electrotransfer: its principles and an updated review of its therapeutic applications , 2004, Gene therapy.

[73]  Jean-Luc Coll,et al.  Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. , 2004, Journal of the American Chemical Society.

[74]  D. Hoekstra,et al.  Characterization and transfection properties of lipoplexes stabilized with novel exchangeable polyethylene glycol-lipid conjugates. , 2004, Biochimica et biophysica acta.

[75]  K. Ugen,et al.  Electroporation as a method for the efficient in vivo delivery of therapeutic genes. , 2003, DNA and cell biology.

[76]  Hideyoshi Harashima,et al.  Pharmacokinetic and pharmacodynamic considerations in gene therapy. , 2003, Drug discovery today.

[77]  L. Seymour,et al.  Nonviral gene delivery: techniques and implications for molecular medicine , 2003, Expert Reviews in Molecular Medicine.

[78]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[79]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[80]  Yadollah Omidi,et al.  Toxicogenomics of Non-viral Vectors for Gene Therapy: A Microarray Study of Lipofectin- and Oligofectamine-induced Gene Expression Changes in Human Epithelial Cells , 2003, Journal of drug targeting.

[81]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[82]  M. Woodle,et al.  siRNA-mediated antitumorigenesis for drug target validation and therapeutics. , 2003, Current opinion in molecular therapeutics.

[83]  D. Weissman,et al.  Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference1 , 2002, The Journal of Immunology.

[84]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[85]  Phillip D Zamore,et al.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. , 2002, Molecular cell.

[86]  Feng Liu,et al.  A syringe electrode device for simultaneous injection of DNA and electrotransfer. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[88]  Y. Barenholz,et al.  Phase Behavior, DNA Ordering, and Size Instability of Cationic Lipoplexes , 2001, The Journal of Biological Chemistry.

[89]  P. Cullis,et al.  On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids , 2001, Gene Therapy.

[90]  Joyce Nelson,et al.  Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys , 2000, Pharmaceutical Research.

[91]  M. D. Brown,et al.  Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. , 2000, Bioconjugate chemistry.

[92]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[93]  D. Fischer,et al.  A Novel Non-Viral Vector for DNA Delivery Based on Low Molecular Weight, Branched Polyethylenimine: Effect of Molecular Weight on Transfection Efficiency and Cytotoxicity , 1999, Pharmaceutical Research.

[94]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[95]  T Salditt,et al.  An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. , 1998, Science.

[96]  Sanchita Bhattacharya,et al.  Characterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene delivery , 1998, Gene Therapy.

[97]  E. Wagner.  Effects of membrane-active agents in gene delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[98]  L. Huang,et al.  In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes , 1997, Gene Therapy.

[99]  J. Baker,et al.  Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.

[100]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[101]  F. Szoka,et al.  Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.

[102]  Leaf Huang,et al.  Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer (*) , 1996, The Journal of Biological Chemistry.

[103]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[104]  L. Huang,et al.  DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. , 1994, Biochimica et biophysica acta.

[105]  S. Swaminathan,et al.  A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. , 1993, Biochemistry.

[106]  R. Timpl,et al.  Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. , 1992, European journal of biochemistry.

[107]  K Zatloukal,et al.  Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[108]  T. Klein,et al.  Transformation of Microbes, Plants and Animals by Particle Bombardment , 1992, Bio/Technology.

[109]  M. Cotten,et al.  Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. Johnston,et al.  Mitochondrial transformation in yeast by bombardment with microprojectiles. , 1988, Science.

[111]  Young-Seung Kim,et al.  Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. , 2009, Molecular pharmaceutics.

[112]  Yun Chen,et al.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  H Akita,et al.  Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid , 2007, Gene Therapy.

[114]  Y. Barenholz,et al.  DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. , 2004, Critical reviews in therapeutic drug carrier systems.

[115]  G. Hannon.  RNA interference : RNA , 2002 .

[116]  Grietje Molema,et al.  Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. , 2002, Bioconjugate chemistry.

[117]  J. Szostak,et al.  In vitro selection of functional nucleic acids. , 1999, Annual review of biochemistry.